Effects of mineralocorticoid receptor antagonists on left ventricular mass in chronic kidney disease patients: a systematic review and meta-analysis

International Urology and Nephrology

Volumn 48, Issue 9, 2016, Pages 1499-1509

  Lu, Ren Jie ^a   Zhang, Yan ^a   Zhu, Xishan ^a   Fan, Zhengda ^a   Zhu, Shanmei ^a   Cui, Manman ^a   Zhang, Yanping ^a   Tang, Fenglei ^a  

^a The Third People s Hospital of Changzhou   (China)

Author keywords

Aldosterone receptor antagonist; Cardiovascular events; Chronic kidney disease; Left ventricular mass; Mortality

Indexed keywords

EPLERENONE; MINERALOCORTICOID ANTAGONIST; POTASSIUM; SPIRONOLACTONE;

ALL CAUSE MORTALITY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR EFFECT; CARDIOVASCULAR PARAMETERS; CHRONIC KIDNEY DISEASE; DISEASE SEVERITY; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; EVIDENCE BASED PRACTICE; GYNECOMASTIA; HEART LEFT VENTRICLE MASS; HUMAN; HYPERKALEMIA; INCIDENCE; LEFT VENTRICULAR MASS INDEX; META ANALYSIS; MORTALITY; OUTCOME ASSESSMENT; POTASSIUM BLOOD LEVEL; PREVALENCE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIDE EFFECT; SYSTEMATIC REVIEW; CARDIOVASCULAR DISEASES; CAUSE OF DEATH; CHEMICALLY INDUCED; COMPLICATION; DRUG EFFECTS; HEART VENTRICLE; HYPERTROPHY, LEFT VENTRICULAR; ORGAN SIZE; PATHOLOGY; PROTECTION; RENAL INSUFFICIENCY, CHRONIC; RISK FACTOR;

CARDIOVASCULAR DISEASES; CAUSE OF DEATH; HEART VENTRICLES; HYPERKALEMIA; HYPERTROPHY, LEFT VENTRICULAR; INCIDENCE; MINERALOCORTICOID RECEPTOR ANTAGONISTS; ORGAN SIZE; PREVALENCE; PROTECTIVE FACTORS; RENAL INSUFFICIENCY, CHRONIC; RISK FACTORS;

EID: 84969808857     PISSN: 03011623     EISSN: 15732584     Source Type: Journal    
DOI: 10.1007/s11255-016-1319-7     Document Type: Review

References (35)

1. Matsushita K, Ballew SH, Coresh J (2015) Influence of chronic kidney disease on cardiac structure and function. Curr Hypertens Rep 17:581
2. Tomino Y (2014) Pathogenesis and treatment of chronic kidney disease: a review of our recent basic and clinical data. Kidney Blood Press Res 39:450–489
3. Gansevoort RT, Correa-Rotter R, Hemmelgarn BR et al (2013) Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention. Lancet 382:339–352
4. Foley RN, Curtis BM, Randell EW et al (2010) Left ventricular hypertrophy in new hemodialysis patients without symptomatic cardiac disease. Clin J Am Soc Nephrol 5:805–813
5. Collins AJ, Li S, Gilbertson DT et al (2003) Chronic kidney disease and cardiovascular disease in the Medicare population. Kidney Int Suppl 87:S24–S31
6. Hill NR, Lasserson D, Thompson B et al (2014) Benefits of Aldosterone Receptor Antagonism in Chronic Kidney Disease (BARACK D) trial-a multi-centre, prospective, randomised, open, blinded end-point, 36-month study of 2616 patients within primary care with stage 3b chronic kidney disease to compare the efficacy of spironolactone 25 mg once daily in addition to routine care on mortality and cardiovascular outcomes versus routine care alone: study protocol for a randomized controlled trial. Trials 15:160
7. Muntner P, He J, Astor BC et al (2005) Traditional and nontraditional risk factors predict coronary heart disease in chronic kidney disease: results from the atherosclerosis risk in communities study. J Am Soc Nephrol 16:529–538
8. Brewster UC, Setaro JF, Perazella MA (2003) The renin-angiotensin-aldosterone system: cardiorenal effects and implications for renal and cardiovascular disease states. Am J Med Sci 326:15–24
9. Pitt B, Zannad F, Remme WJ et al (1999) The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study investigators. N Engl J Med 341:709–717
10. Zannad F, McMurray JJ, Krum H et al (2011) Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 364:11–21
11. Vukusich A, Kunstmann S, Varela C et al (2010) A randomized, double-blind, placebo-controlled trial of spironolactone on carotid intima-media thickness in nondiabetic hemodialysis patients. Clin J Am Soc Nephrol 5:1380–1387
12. Pitt B, Kober L, Ponikowski P et al (2013) Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial. Eur Heart J 34:2453–2463
13. Boesby L, Elung-Jensen T, Strandgaard S et al (2013) Eplerenone attenuates pulse wave reflection in chronic kidney disease stage 3-4–a randomized controlled study. PLoS ONE 8:e64549
14. Taheri S, Mortazavi M, Pourmoghadas A et al (2012) A prospective double-blind randomized placebo-controlled clinical trial to evaluate the safety and efficacy of spironolactone in patients with advanced congestive heart failure on continuous ambulatory peritoneal dialysis. Saudi J Kidney Dis Transpl 23:507–512
15. Chung YW, Yang YH, Wu CK et al (2016) Spironolactone is associated with reduced risk of new-onset atrial fibrillation in patients receiving renal replacement therapy. Int J Cardiol 202:962–966
16. Bomback AS (2016) Mineralocorticoid receptor antagonists in end-stage renal disease: efficacy and safety. Blood Purif 41:166–170
17. Walsh M, Manns B, Garg AX et al (2015) The safety of eplerenone in hemodialysis patients: a noninferiority randomized controlled trial. Clin J Am Soc Nephrol 10:1602–1608
18. Stroup DF, Berlin JA, Morton SC et al (2000) Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis of Observational Studies in Epidemiology (MOOSE) group. JAMA 283:2008–2012
19. Feniman-De-Stefano GM, Zanati-Basan SG, De Stefano LM et al (2015) Spironolactone is secure and reduces left ventricular hypertrophy in hemodialysis patients. Ther Adv Cardiovasc Dis 9:158–167
20. Edwards NC, Steeds RP, Stewart PM et al (2009) Effect of spironolactone on left ventricular mass and aortic stiffness in early-stage chronic kidney disease: a randomized controlled trial. J Am Coll Cardiol 54:505–512
21. Vardeny O, Wu DH, Desai A et al (2012) Influence of baseline and worsening renal function on efficacy of spironolactone in patients With severe heart failure: insights from RALES (Randomized Aldactone Evaluation Study). J Am Coll Cardiol 60:2082–2089
22. Flevari P, Kalogeropoulou S, Drakou A et al (2013) Spironolactone improves endothelial and cardiac autonomic function in non heart failure hemodialysis patients. J Hypertens 31:1239–1244
23. Eschalier R, McMurray JJ, Swedberg K et al (2013) Safety and efficacy of eplerenone in patients at high risk for hyperkalemia and/or worsening renal function: analyses of the EMPHASIS-HF study subgroups (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure). J Am Coll Cardiol 62:1585–1593
24. Ito Y, Mizuno M, Suzuki Y et al (2014) Long-term effects of spironolactone in peritoneal dialysis patients. J Am Soc Nephrol 25:1094–1102
25. Inampudi C, Parvataneni S, Morgan CJ et al (2014) Spironolactone use and higher hospital readmission for Medicare beneficiaries with heart failure, left ventricular ejection fraction <45%, and estimated glomerular filtration rate <45 ml/min/1.73 m(2.). Am J Cardiol 114:79–82
26. Matsumoto Y, Mori Y, Kageyama S et al (2014) Spironolactone reduces cardiovascular and cerebrovascular morbidity and mortality in hemodialysis patients. J Am Coll Cardiol 63:528–536
27. Hassan M, Qureshi W, Sroujieh LS et al (2014) Interplay of parathyroid hormone and aldosterone antagonist in prevention of heart failure hospitalizations in chronic kidney disease. J Renin Angiotensin Aldosterone Syst 15:278–285
28. Oh J, Kang SM, Song MK et al (2015) Clinical benefit of spironolactone in patients with acute decompensated heart failure and severe renal dysfunction: data from the Korean Heart Failure Registry. Am Heart J 169(713–720):e3
29. Lin C, Zhang Q, Zhang H et al (2016) Long-term effects of low-dose spironolactone on chronic dialysis patients: a randomized Placebo-Controlled Study. J Clin Hypertens (Greenwich) 18:121–128
30. Taheri S, Mortazavi M, Shahidi S et al (2009) Spironolactone in chronic hemodialysis patients improves cardiac function. Saudi J Kidney Dis Transpl 20:392–397
31. Agarwal R (2010) Blood pressure and mortality among hemodialysis patients. Hypertension 55:762–768
32. Iraqi W, Rossignol P, Angioi M et al (2009) Extracellular cardiac matrix biomarkers in patients with acute myocardial infarction complicated by left ventricular dysfunction and heart failure: insights from the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS) study. Circulation 119:2471–2479
33. Voelkl J, Alesutan I, Leibrock CB et al (2013) Spironolactone ameliorates PIT1-dependent vascular osteoinduction in klotho-hypomorphic mice. J Clin Invest 123:812–822
34. Brown NJ (2013) Contribution of aldosterone to cardiovascular and renal inflammation and fibrosis. Nat Rev Nephrol 9:459–469
35. Kannan A, Poongkunran C, Balamuthusamy S (2014) Effect of spironolactone in CV mortality in hemodialysis patients. J Am Coll Cardiol 64:528–529